Review of combination therapies for neovascular age-related macular degeneration

Keyphrases

• Combination Therapy 100%
• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Monotherapy 66%
• Clinical Trials 33%
• Inflammation 33%
• Standard of Care 33%
• Oxidative Stress 33%
• Angiogenesis 33%
• Age-related Macular Degeneration 33%
• Treatment Efficacy 33%
• Triple Therapy 33%
• Multiple Mechanisms 33%
• Photodynamic Therapy 33%
• Visual Outcome 33%
• Anti-VEGF Therapy 33%
• Reducing Treatment 33%
• Intravitreal Anti-vascular Endothelial Growth Factor Injection 33%
• Double Therapy 33%
• Intravitreal Steroids 33%
• Reduced Fluence 33%

Medicine and Dentistry

• Combination Therapy 100%
• Wet Macular Degeneration 100%
• Monotherapy 66%
• Vasculotropin 66%
• Clinical Trial 33%
• Angiogenesis 33%
• Age Related Macular Degeneration 33%
• Oxidative Stress 33%
• Photochemotherapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Combination Therapy 100%
• Wet Macular Degeneration 100%
• Monotherapy 66%
• Vasculotropin 66%
• Clinical Trial 33%
• Inflammation 33%
• Age Related Macular Degeneration 33%
• Photodynamic Therapy 33%